82 related articles for article (PubMed ID: 24073318)
1. A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer.
Woo SM; Lee SH; Yoo JW; Yang KY; Seo JG; Park JK; Hwang JH; Lee WJ; Ryu JK; Kim YT; Yoon YB
Gut Liver; 2013 Sep; 7(5):594-8. PubMed ID: 24073318
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
Sharma A; Pramanik R; Kumar A; Pathy S; Kumar S; Bhoriwal S; Thulkar S; Dash NR; Pal S; Choudhary P; Pawar S; Kumar R; Gupta G
JCO Glob Oncol; 2021 Jun; 7():820-826. PubMed ID: 34086477
[TBL] [Abstract][Full Text] [Related]
3. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen.
Cui XY; Li XC; Cui JJ; Wu XS; Zou L; Song XL; Ren T; Zhu YD; Li HF; Yang Y; Liu K; Han XS; Jia ZY; Wu WG; Wang XA; Gong W; Wang LW; Li ML; Liu YB
Hepatobiliary Surg Nutr; 2021 Aug; 10(4):498-506. PubMed ID: 34430528
[TBL] [Abstract][Full Text] [Related]
4. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S; Ziras N; Vamvakas L; Varthalitis J; Papakotoulas P; Syrigos K; Vardakis N; Kalykaki A; Amarantidis K; Georgoulias V
Lung Cancer; 2006 Dec; 54(3):347-52. PubMed ID: 17030075
[TBL] [Abstract][Full Text] [Related]
6. Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.
Yang Z; Wu Z; Xiong Y; Liu S; Cai C; Shao Z; Zhu Y; Song X; Shen W; Wang X; Wu X; Gong W
Front Oncol; 2022; 12():977963. PubMed ID: 36052238
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study.
Passardi A; Scarpi E; Neri E; Parisi E; Ghigi G; Ercolani G; Gardini A; La Barba G; Pagan F; Casadei-Gardini A; Valgiusti M; Ferroni F; Frassineti GL; Romeo A
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31086093
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
André T; Reyes-Vidal JM; Fartoux L; Ross P; Leslie M; Rosmorduc O; Clemens MR; Louvet C; Perez N; Mehmud F; Scheithauer W
Br J Cancer; 2008 Sep; 99(6):862-7. PubMed ID: 19238628
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Okano N; Morizane C; Nomura S; Takahashi H; Tsumura H; Satake H; Mizuno N; Tsuji K; Shioji K; Asagi A; Yasui K; Kitagawa S; Kashiwada T; Ishiguro A; Kanai M; Ueno M; Ogura T; Shimizu S; Tobimatsu K; Motoya M; Nakashima K; Ikeda M; Okusaka T; Furuse J
Int J Clin Oncol; 2020 Oct; 25(10):1835-1843. PubMed ID: 32535711
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab based chemotherapy is a promising option in metastatic gallbladder adenocarcinoma.
Aagre SV; Tonse M; Talele A; Sharma S; Advani SH
Mol Clin Oncol; 2021 Aug; 15(2):153. PubMed ID: 34178324
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer.
Lagenfelt H; Blomstrand H; Elander NO
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298723
[TBL] [Abstract][Full Text] [Related]
14. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.
Chen JS; Chen YY; Huang JS; Yeh KY; Chen PT; Shen WC; Hsu HC; Lin YC; Wang HM
Gastric Cancer; 2012 Jan; 15(1):49-55. PubMed ID: 21655995
[TBL] [Abstract][Full Text] [Related]
15. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
16. A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer.
Driesen P; Lambrechts M; Kraaij K; Soldatenkova V; Chouaki N; Colinet B
Ther Adv Med Oncol; 2013 May; 5(3):159-68. PubMed ID: 23634194
[TBL] [Abstract][Full Text] [Related]
17. Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.
Hollebecque A; Bouché O; Romano O; Scaglia E; Cattan S; Zerbib P; Heurgue A; Lagarde S; Mariette C; Triboulet JP; Pruvot FR; Hebbar M
Chemotherapy; 2010; 56(3):234-8. PubMed ID: 20551640
[TBL] [Abstract][Full Text] [Related]
18. Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder.
Sharma M; Talwar V; Maheshwari U; Koyyala VPB; Goel V; Goyal S; Dash PK; Batra U; Bajaj R; Yadav A; Goyal P; Doval DC
South Asian J Cancer; 2020 Oct; 9(4):204-208. PubMed ID: 34131572
[No Abstract] [Full Text] [Related]
19. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.
Paule B; Herelle MO; Rage E; Ducreux M; Adam R; Guettier C; Bralet MP
Oncology; 2007; 72(1-2):105-10. PubMed ID: 18025804
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
